Veru to Report Fiscal 2021 First-Quarter Financial Results, Host Conference Call on February 10thGlobeNewsWire • 01/27/21
Veru to Present at the H.C. Wainwright Bioconnect 2021 Conference on January 11th, 2021GlobeNewsWire • 01/04/21
Veru's stock soars again on heavy volume after positive results of breast cancer treatmentMarket Watch • 12/14/20
VERU Stock News: 9 Things for Investors to Know About Veru Breast Cancer Trial ResultsInvestorPlace • 12/14/20
Do Options Traders Know Something About Veru (VERU) Stock We Don't?Zacks Investment Research • 12/14/20
Veru Reports Positive Phase 2 Clinical Trial Results for Enobosarm, Selective Androgen Receptor Targeting Agent, for Endocrine Resistant Metastatic Breast CancerGlobeNewsWire • 12/14/20
VERU-111, Cytoskeleton Disruptor, Demonstrates Efficacy in Preclinical Models of Human Triple Negative Breast CancerGlobeNewsWire • 12/14/20
Veru, Inc. (VERU) CEO Mitchell Steiner on Q4 2020 Results - Earnings Call TranscriptSeeking Alpha • 12/09/20
Veru Expands Oncology Drug Pipeline; Exclusively Licenses Phase 3 Clinical Stage Targeted Therapy for Endocrine Resistant Metastatic Breast CancerGlobeNewsWire • 12/09/20
Veru Reports Record Fiscal 2020 Fourth Quarter and Record Full-Year Financial ResultsGlobeNewsWire • 12/09/20
Veru to Report Fiscal 2020 Fourth-Quarter, Full-Year Financial Results, Host Conference Call on December 9thGlobeNewsWire • 11/23/20
Veru Completes Enrollment of Phase 2 Clinical Trial of VERU-111, Novel Oral Drug for Metastatic Prostate CancerGlobeNewsWire • 09/29/20
Veru Announces ESMO Congress 2020 Oral Presentation of Positive Clinical Results from its VERU-111 Phase 1b Study in Metastatic Prostate CancerGlobeNewsWire • 09/18/20
Veru to Participate and Present at Four Upcoming Healthcare Investor ConferencesGlobeNewsWire • 09/09/20
Veru Inc. (VERU) CEO Mitchell Steiner on Q3 2020 Results - Earnings Call TranscriptSeeking Alpha • 08/13/20
VERU-111 Suppresses Key Cytokines Responsible for Severe Acute Respiratory Distress Syndrome in COVID-19GlobeNewsWire • 08/04/20
Veru to Report Fiscal 2020 Third-Quarter Financial Results, Host Conference Call on August 13thGlobeNewsWire • 07/30/20
Veru Announces ESMO Congress 2020 Acceptance of VERU-111, a Novel Oral Tubulin Targeting Agent, Phase 1b/2 Study in Metastatic Prostate Cancer as an Oral PresentationGlobeNewsWire • 07/27/20